Non-CNE Symposia

10:45 am – 12:00 pm
Thursday, September 3

Clinical Pearls: Nurse’s Role in Achieving Optimal Chelation in Patients With Transfusion-Dependent Thalassemia (SY2)

When patients with transfusion-dependent thalassemia (TDT) move into adulthood, understanding the importance of iron-overload and adherence to chelation is paramount. A nurse expert will review clinical pearls and a TDT patient will share real-world experience to help participants gain best practices on the nurse’s role in helping patients achieve optimal chelation.

APHON thanks Chiesi for their generous support of this event.

 

10:45 am – 12:00 pm
Friday, September 4

Giving Subcutaneous Prophylaxis a Shot in Hemophilia A (SY3)

Join us for a nurse and patient-led symposium on a subcutaneous prophylaxis option for patients with hemophilia A. The panelists will discuss practical considerations for hemophilia A management, including dosing and administration, key clinical trial data, and patient support. Questions will be answered by the panelists during the program.

 

APHON thanks Genentech for their generous support of this event.

Wednesday, September 2
2:00 – 3:15 pm

Rising to The Challenge of Identifying and Treating Hepatic VOD Post HSCT: A Case-Based Approach

A case-based discussion of veno-occlusive disease (VOD) following HSCT. Topics include identifying factors that put patients at a greater risk for VOD, recognizing the signs and symptoms of VOD, and reviewing newly published diagnostic criteria in order to build confidence in making an early and accurate diagnosis of VOD.

APHON thanks Jazz Pharmaceuticals for their generous support of this event.

Speaker:

Kenneth Cooke, MD
Mitchell Cairo, MD

2:00 am – 3:15 pm
Wednesday, September 2

Rising to the Challenge of Identifying and Treating Hepatic VOD Post HSCT: A Case-Based Approach (SY4)

A case-based discussion of veno-occlusive disease (VOD) following HSCT. Topics include identifying factors that put patients at a greater risk for VOD, recognizing the signs and symptoms of VOD, and reviewing newly published diagnostic criteria in order to build confidence in making an early and accurate diagnosis of VOD.

APHON thanks Jazz Pharmaceuticals for their generous support of this event